Interestingly, we found high expression of UNC93B1 just linked to worse prognosis in AML patients without FLT3 (p < 0.05, Supplementary Figure S2A), IDH1 (p < 0.05, Supplementary Figures S2B–D) or NRAS (p < 0.05, Supplementary Figure S2H) mutation, once acquired mutations of these genes, UNC93B1 expression level had no effects on patient’s survival outcome (p > 0.05, Supplementary Figures S2E–G). This evidence concerns the gene UNC93B1 and acute myeloid leukemia.